title: Effect of centrally administered C75, a fatty acid synthase inhibitor, on gastric emptying and gastrointestinal transit in mice.
abstract: The central or systemic administration of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75), a synthetic inhibitor of fatty acid synthase (FAS), causes anorexia and profound weight loss in rodents. The amount of food intake and gastrointestinal mobility are closely related. In this study, an attempt has been made to investigate the effects and mechanisms of C75 on gastric emptying and gastrointestinal transit after intracerebroventricular (i.c.v.) injection in mice. Our data showed that C75 (1, 5, 10 microg/mouse) dose-dependently delayed gastric emptying and gastrointestinal transit in fasted mice. 10 microg C75 delayed gastric emptying by about 21.4% and reduced gastrointestinal transit by about 31.0% compared with vehicle control group. Administration (i.c.v.) of 5-(tetradecyloxy)-2-furoic acid (TOFA, an acetyl-CoA carboxylase (ACC) inhibitor) or ghrelin attenuated the delayed gastrointestinal mobility effect induced by 10 microg C75. Taken together, C75 is able to decrease gastrointestinal mobility and it seems possible that malonyl-CoA and ghrelin might play an intermediary role in these processes.
authors.affiliation: Institute of Biochemistry and Molecular Biology, School of Life Science, Lanzhou University, Lanzhou, China.
authors.forename: Lai-Fu
authors.initials: LF
authors.lastname: Li
authors.forename: Yan-Yu
authors.initials: YY
authors.lastname: Lu
authors.forename: Wei
authors.initials: W
authors.lastname: Xiong
authors.forename: Juan-Ying
authors.initials: JY
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
mesh_terms: D015107:4-Butyrolactone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005215:Fasting; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005663:Furans / Q000008:administration & dosage; D005746:Gastric Emptying / Q000187:drug effects*; D005772:Gastrointestinal Transit / Q000187:drug effects*; D054439:Ghrelin / Q000008:administration & dosage; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice
chemical_list: C406734:4-methylene-2-octyl-5-oxofuran-3-carboxylic acid; D004791:Enzyme Inhibitors; D005663:Furans; D054439:Ghrelin; C014289:5-(tetradecyloxy)-2-furancarboxylic acid; D064429:Fatty Acid Synthases; D000103:Acetyl-CoA Carboxylase; D015107:4-Butyrolactone